About the Webinar
Over the past decade, considerable progress has been made in improving the effectiveness and efficiency of generating highly-productive recombinant CHO cell lines. These improvements are now the underpinning of bioprocess development and involve both advancements in cell line generation and cell culture process development. While these efforts have been primarily centered on driving cell culture productivity, more recently, focus has turned to approaches to impact product quality. Specifically, host engineering capabilities have been directed to successfully edit CHO cell lines to improve product quality profiles of bio-therapeutic proteins. Given the labor-intensive, inefficient and time-consuming nature of such capability application, a significant need exists to find creative approaches to maximize the effectiveness, while minimizing the impact of such efforts to timelines. This presentation will describe potential approaches to maximizing the effectiveness of host cell engineering and reducing the time to successfully impact bio-therapeutic product quality profiles.
About the Presenter
Stephanie received a B.S. degree in Microbiology from Purdue University, and an M.S. degree in Microbiology/Immunology from Vanderbilt University. She joined Eli Lilly and Company in 2000, beginning her career in the Discovery organization specifically the Department of Infection Diseases, developing a mouse model in which to evaluate anti-HCV compounds. Stephanie later transitioned to Bioprocess Research and Development in 2003 to develop microbial expression technologies for the production of therapeutic proteins. In 2007, she moved to the Molecular and Cellular Biology Group which is responsible for supporting all of Lilly’s mammalian-based manufacturing processes. Most recently, Stephanie has helped develop and establish state-of-the-art cell line engineering capabilities at Lilly.
